09.09.26 -- What Baby KJ Taught Us About mRNA COGS

The Alliance for mRNA Medicines' ASCENT meeting (Advancements in mRNA Science, Commercialization, Education, and Novel Technologies) is the must-attend conference for stakeholders in the mRNA industry. With one-on-one partnering and dedicated networking opportunities, sessions led by industry visionaries and KOLs, and engaging panel discussions featuring biotech, pharma, and academic leaders, join us in advancing RNA research into vaccines and therapies for patients. Register here today!

Here, in part 2 of this three-part series, I share a few details that came to light about the COGS behind Baby KJ’s therapy production. Obviously, we know why it’s important to keep these figures in mind as we move forward; but I particularly liked Strauss’ reminder that it’s our job to “think systematically about how we’re going to create a safety net of sustainable, accessible product that can be widely distributed at an affordable cost.”

As RNA therapeutics grow more complex, better biological annotation is becoming the foundation for AI-driven discovery, target selection, and smarter drug development.

CircRNA location may be as important as its sequence. Discover how nuclear organization could influence the next generation of RNA therapeutics.

Chemoenzymatic ligation could overcome the scalability and sustainability limits of traditional oligonucleotide manufacturing, enabling more efficient RNA drug production.